Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I-Ib/II Open-label Multi-center Study of the Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies

Trial Profile

Phase I-Ib/II Open-label Multi-center Study of the Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 11 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Decitabine (Primary) ; Sabatolimab (Primary) ; Spartalizumab (Primary)
  • Indications Advanced breast cancer; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Gastric cancer; Gastrointestinal stromal tumours; Head and neck cancer; Liver cancer; Malignant melanoma; Merkel cell carcinoma; Mesothelioma; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Sarcoma; Small cell lung cancer; Solid tumours; Urogenital cancer; Uveal neoplasms
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
  • Most Recent Events

    • 20 Sep 2022 Status changed from active, no longer recruiting to discontinued due to business reasons.
    • 18 Sep 2022 This trial has been discontinued in Netherland, according European Clinical Trials Database record.
    • 15 Jul 2022 Planned End Date changed from 25 Jul 2022 to 29 Aug 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top